Journal
CRITICAL CARE
Volume 20, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13054-016-1320-7
Keywords
-
Categories
Funding
- Bayer
- Pfizer
- Basilea
- Astellas
- Cubist-Merck
- Kenta-Aridis
- Medimmune-AstraZeneca
- Abbott Laboratories
- Actelion
- Astra-Zeneca
- Cerexa
- Cubist
- Durata
- European Tissue Symposium
- Medicines Company
- MedImmune
- Merck
- Motif Biosciences
- Nabriva
- Optimer
- Paratek
- Roche
- Sanofi-Pasteur
- Seres
- Summit
- Synthetic Biologics
- Abbott
- Alere
- bioMerieux
- Da Volterra
Ask authors/readers for more resources
The rapid emergence and dissemination of antibiotic-resistant microorganisms in ICUs worldwide threaten adequate antibiotic coverage of infected patients in this environment. The causes of this problem are multifactorial, but the core issues are clear: the emergence of antibiotic resistance is highly correlated with selective pressure resulting from inappropriate use of these drugs. Because a significant increase in mortality is observed when antibiotic therapy is delayed in infected ICU patients, initial therapy should be broad enough to cover all likely pathogens. Receipt of unnecessary prolonged broad-spectrum antibiotics, however, should be avoided. Local microbiologic data are extremely important to predict the type of resistance that may be present for specific causative bacteria, as is prior antibiotic exposure, and antibiotic choices should thus be made at an individual patient level.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available